Notably, the novel SIRT3 inhibitor, LC-0296, exhibited enhanced selectivity toward SIRT3 enzyme, promoting HNSCC cell apoptosis and reducing cell viability when employed alongside radiation or cisplatin therapy [97]. Here, SIRT3 is linked to head and neck squamous cell carcinoma.